Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, CS, R2, and R3 are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Abstract: In one aspect, a movable barrier operator system is provided that includes a motor configured to be coupled to a movable barrier. The motor has a power rating indicative of a minimum power to be supplied to the motor in order for the motor to move the movable barrier. The system further includes an external power supply configured to connect to an electrical outlet. The external power supply has a plurality of outputs each having a power rating indicative of a maximum power the output supplies, the output power rating being less than the motor power rating. The movable barrier operator system includes combiner circuitry configured to combine power from the outputs of the external power supply and provide the combined power to the motor. The system further includes a monitoring circuit configured to detect a fault condition of any of the outputs of the external power supply.

Abstract: Disclosed is a method of receiving and processing content-sending inputs received by a head-worn device system including one or more display devices, one or more cameras and a vertically-arranged touchpad. The method includes displaying a content item on the one or more display devices, receiving a touch input on the touchpad corresponding to a send instruction, displaying a carousel of potential recipients, receiving a horizontal touch input on the touchpad, scrolling the carousel left or right on the one or more display devices in response to the horizontal touch input, receiving a tap touch input on the touchpad to select a particular recipient, receiving a further touch input, and in response to the further touch input, transmitting the content item to the selected recipient.

Abstract: Disclosed is a method of receiving and processing navigation inputs executed by one or more processors in a head-worn device system including one or more display devices, one or more cameras and a generally vertically-arranged touchpad. The method comprises displaying a first carousel of AR effects icons, receiving a first horizontal input on the touchpad, rotating the first carousel of AR effects icons in response to first horizontal input, receiving a first touch input on the touchpad to select a particular AR effects icon that is in a selection position in the first carousel, displaying a scene viewed by the one or more cameras, the scene being enhanced with AR effects corresponding to the particular AR effects icon, receiving content capture user input, and in response to the content capture user input, capturing a new content item corresponding to the scene.

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: A permission based media system to perform operations that include: presenting a first media object at a client device associated with a user account, the first media object including a reference that identifies the user account; receiving an input that selects the first media object from the client device; determining a permission of the user account based on the reference that identifies the user account; presenting a set of options based on the permission associated with the user account; receiving a selection of an option from among the set of options; and generating a second media object based on the first media object and the selection of the option, according to certain embodiments.

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.

Abstract: A method and system for deploying an application from a deployment source to a device may include determining if the application is available for deployment to the device from a plurality of deployment sources, upon determining that the application is available for deployment from the plurality of deployment sources, identifying one of the plurality of deployment sources as a preferred deployment source for deploying the application; and deploying the application from the preferred deployment source to the device. Deploying the application may include installing the application, loading one or more user interface elements associated with the application and activating the application.

Abstract: A method for detecting an exit of a patient from a hospital bed, the method comprising: detecting a presence of the patient on the bed, upon detection of the patient on the bed, monitoring an indication that the patient has moved from a predetermined patient area on a patient receiving surface of the bed to outside the predetermined patient area, upon detection that the patient has moved outside the predetermined patient area, activating a bed alarm to indicate to a user that an exit of the patient from the hospital bed has been detected, and after monitoring the indication that the patient has moved from the predetermined patient area and further upon receiving a pause command, suspending monitoring the indication that the patient has moved from the predetermined patient area. There is also provided a system for detecting an exit of a patient from a hospital bed.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: A method for detecting an exit of a patient from a hospital bed, the method comprising: detecting a presence of the patient on the bed, upon detection of the patient on the bed, monitoring an indication that the patient has moved from a predetermined patient area on a patient receiving surface of the bed to outside the predetermined patient area, upon detection that the patient has moved outside the predetermined patient area, activating a bed alarm to indicate to a user that an exit of the patient from the hospital bed has been detected, and after monitoring the indication that the patient has moved from the predetermined patient area and further upon receiving a pause command, suspending monitoring the indication that the patient has moved from the predetermined patient area. There is also provided a system for detecting an exit of a patient from a hospital bed.

Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1 and R2 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: A hospital bed height limiting system comprising a processing unit operatively connected to each of a user interface, an elevation mechanism of the hospital bed and a height sensor. The processing unit is operable to receive a minimum height via the user interface and receive from the height sensor a current elevation mechanism height. The processing unit is operable to determine the bed height based on the current elevation mechanism height, and in response to the bed height being equal to the minimum height, the processing unit is operable to cause the elevation mechanism to stop a downward movement of the elevation mechanism. A hospital bed comprising the hospital bed height limiting system is also provided.

Abstract: A method and system for deploying an application from a deployment source to a device may include determining if the application is available for deployment to the device from a plurality of deployment sources, upon determining that the application is available for deployment from the plurality of deployment sources, identifying one of the plurality of deployment sources as a preferred deployment source for deploying the application; and deploying the application from the preferred deployment source to the device. Deploying the application may include installing the application, loading one or more user interface elements associated with the application and activating the application.